The IPO queue adds 5 more biotechs hop­ing to ring in 2021 by blitz­ing Nas­daq

Fol­low­ing a record year for IPOs — in terms of both pro­ceeds and count — there’s al­ready a long line­up of biotechs ready to jump on­to Nas­daq in the new year. The com­pa­nies are like­ly look­ing for much high­er rais­es than they ini­tial­ly pro­ject­ed on their S-1s. Now it’s time to see if in­vestors are still hun­gry for an­oth­er round of biotech stocks.

Sana helped set the pace ear­ly on, as its founders look to divvy up a for­tune from their IPO. And late last week 5 more biotechs crowd­ed in, look­ing to pick up the pace where 2020 left off. Here they are:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER